LIQUIDIA CORP. news, videos and press releases
For more news please use our advanced search feature.
LIQUIDIA CORP. - More news...
LIQUIDIA CORP. - More news...
- Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
- Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
- Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024
- Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress
- Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
- Liquidia Corporation Announces Updates to Operations Leadership
- Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims
- Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD
- Liquidia Corporation Announces $100 Million in New Financings
- Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
- U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)
- Liquidia Announces Pricing of Public Offering of Common Stock
- Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023
- FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Label
- United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office
- Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023
- Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder
- U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation
- Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America
- Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference
- Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference
- Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference
- Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023
- Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference
- Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications
- Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update